Welcome to our dedicated page for Rein Therapeutics news (Ticker: RNTX), a resource for investors and traders seeking the latest updates and insights on Rein Therapeutics stock.
Rein Therapeutics, Inc. (NASDAQ: RNTX) is a clinical-stage biopharmaceutical company focused on first-in-class therapies for idiopathic pulmonary fibrosis (IPF) and other orphan pulmonary and fibrosis indications. The RNTX news feed highlights company announcements, scientific publications, regulatory updates, clinical milestones, and financing developments that shape the outlook for its pipeline.
Investors and observers can follow detailed updates on LTI-03, Rein’s lead Caveolin-1–related peptide candidate for IPF. Recent news has covered initiation and progress of the global Phase 2 RENEW trial, including first patient dosing, regulatory authorizations from the U.K. MHRA and the European Medicines Agency for sites in the United Kingdom, Germany, and Poland, and the U.S. Food and Drug Administration’s decision to lift a full clinical hold on the U.S. portion of the study.
The news stream also features translational and clinical science, such as peer-reviewed and preprint publications describing LTI-03’s anti-fibrotic activity in ex vivo lung tissue from IPF patients and inhaled dose-escalation studies assessing safety, pharmacokinetics, and biomarker changes. These reports discuss reductions in fibrosis-associated biomarkers, effects on multiple scarring pathways, and preservation of alveolar epithelial type II progenitor cells.
Additional coverage includes updates on LTI-01 for loculated pleural effusions, corporate and governance events such as annual meeting notices and adjournments, and capital markets activity, including pre-paid advance and standby equity purchase agreements and their subsequent termination. By reviewing RNTX news, readers can track how Rein Therapeutics communicates clinical progress, regulatory interactions, and strategic financing decisions that influence its development programs.
Rein Therapeutics (RNTX) will present a late-breaking poster at the European Respiratory Society (ERS) 2026 Congress in Barcelona, Spain, on September 8, 2026.
The poster, titled “Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study”, will be presented in the session “Immunological mechanisms in pulmonary fibrosis” (Poster PA6217) from 12:30–2:00pm CEST by Philip Molyneaux, MD. The company notes that the data have been published in Nature Communications.
Rein Therapeutics (RNTX) will present at two investor conferences in September 2026. President and CEO Brian Windsor is scheduled to speak at the 2026 Cantor Global Healthcare Conference on September 11, 2026, at 8:00 a.m. ET in New York, NY, and at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m. ET, also in New York.
A live webcast of both presentations will be available through the Investors section of the company’s website, with archived replays accessible for approximately 90 days after the events.
Rein Therapeutics (NASDAQ: RNTX) announced that the U.S. FDA has granted Fast Track designation to its lead candidate LTI-03 for treating idiopathic pulmonary fibrosis (IPF). Fast Track is intended to speed development and review of therapies for serious conditions with unmet medical needs and can allow more frequent FDA interaction, rolling submissions, and potential consideration for Accelerated Approval and Priority Review.
LTI-03, previously granted Orphan Drug designation for IPF, is a first-in-class inhaled peptide designed to inhibit lung scarring while preserving alveolar progenitor cells, aiming to slow fibrosis and support lung repair. The ongoing RENEW Phase 2 randomized, placebo-controlled trial plans to enroll about 120 IPF patients across the U.S., U.K., Australia, Poland, and Germany, with safety through Week 24 as the primary endpoint and change in forced vital capacity as the primary efficacy endpoint. According to Rein Therapeutics, interim data are expected in the second half of 2026.
Rein Therapeutics (NASDAQ:RNTX) reported second quarter 2026 results and a business update, highlighting progress of its global Phase 2 RENEW trial of inhaled LTI-03 in idiopathic pulmonary fibrosis (IPF). The company has surpassed 25% of planned enrollment (≈120 patients) across the U.S., U.K., Australia, Germany and Poland, with enrollment tracking ahead of schedule and interim data expected in the second half of 2026.
Rein completed an oversubscribed $57.5 million underwritten public offering, which, together with existing cash, is expected to fund operations and fully finance the RENEW trial into the first quarter of 2028. A peer-reviewed first-in-human LTI-03 study showing reductions in markers of lung scarring was published in Nature Communications in July 2026.
As of June 30, 2026, cash, cash equivalents and marketable securities were $43.6 million. Second quarter R&D expense was $3.6 million (down from $4.3 million a year earlier), G&A was $2.4 million (vs. $2.6 million), and net loss was $6.4 million (vs. $6.8 million).
Rein Therapeutics (NASDAQ:RNTX) reported that first-in-human clinical data for its inhaled IPF candidate LTI-03 have been published in peer-reviewed journal Nature Communications. The randomized, placebo-controlled dose-escalation study enrolled 24 idiopathic pulmonary fibrosis patients treated with 5 or 10 mg/day LTI-03 or placebo for 14 days.
According to Rein Therapeutics, LTI-03 was well-tolerated at both doses, with only mild or moderate side effects and no treatment-related discontinuations, and showed no systemic absorption. Samples from deep lung regions showed statistically significant reductions in multiple biomarkers of fibrosis and inflammation, including IL-11 and TSLP at both doses, and COL1A1, CXCL7, galectin-7, plus a trend toward reduced SP-D at the higher dose. The company said these results support the scientific rationale and design of its ongoing RENEW Phase 2 trial, which aims to enroll about 120 IPF patients to assess safety, tolerability, and lung function (FVC change).
Rein Therapeutics (NASDAQ: RNTX) reported that its randomized, placebo-controlled Phase 2 RENEW trial of inhaled LTI-03 in idiopathic pulmonary fibrosis is now open and enrolling across all five planned countries: the United States, United Kingdom, Australia, Poland, and newly added Germany, with a target of about 120 patients.
The study evaluates two dose levels of LTI-03 versus placebo, with change from baseline in forced vital capacity (FVC) as the major efficacy endpoint. According to Rein Therapeutics, enrollment is progressing and initial topline data are expected in the second half of 2026. LTI-03 is a first-in-class, inhaled peptide derived from Caveolin-1 biology, designed to inhibit lung scarring while preserving alveolar progenitor cells. Early data from a Phase 1b study have been published in Nature Communications. The company also highlights LTI-03’s U.S. Orphan Drug Designation and its second candidate, LTI-01, which has completed Phase 1b and Phase 2a trials and holds orphan and Fast Track designations.
Rein Therapeutics (NASDAQ:RNTX) reported progress in its Phase 2 RENEW trial evaluating LTI-03 in idiopathic pulmonary fibrosis (IPF). The first patient has been randomized in the United Kingdom, bringing total enrollment to 16 patients across the United States, Australia, and the UK.
According to Rein Therapeutics, clinical sites in two additional countries are expected to start enrollment in the coming months, further expanding the global footprint of the RENEW study.
Rein Therapeutics (NASDAQ:RNTX) closed a $57.5 million underwritten public offering of common stock, including full exercise of the underwriters’ over-allotment option.
The company sold 57.5 million shares at $1.00, with no warrants, and expects proceeds to fund its Phase 2 LTI-03 IPF trial and operations into Q1 2028.
Rein Therapeutics (NASDAQ: RNTX) priced an underwritten public offering of 50.0 million common shares at $1.00 per share for gross proceeds of $50 million, with a 45‑day option to purchase up to an additional 7.5 million shares. The offering is expected to close on or about May 4, 2026.
Rein intends to use net proceeds to fully fund its ongoing Phase 2 trial of LTI‑03 in idiopathic pulmonary fibrosis and for working capital; it believes proceeds plus cash on hand will fund operations into 2028.
Rein Therapeutics (NASDAQ: RNTX) provided a Phase 2 RENEW trial update for LTI-03 in idiopathic pulmonary fibrosis. Enrollment began in March 2026; the study has enrolled 8 patients with 2 additional patients expected this week.
Clinical sites are active in the United States, Australia, and Poland, and the company expects to open sites in the United Kingdom and Germany soon to support ongoing enrollment.